Current Management of Vitreomacular Interface Disorders
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Details
Overview
This certified CME activity will be designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.Jointly sponsored by the Dulaney Foundation and Retina Today. Supported by an educational grant from ThromboGenics. This continuing medical educational activity is supported by an unrestricted educational grant from ThromboGenics. Learning Objectives
Upon completion of this activity, the participant should be able to: - Explain the process by which VMA occurs
- Identify the disease states with which VMA is associated
- Identify the clinical implications of anomalous PVD
- Explain the mechanism of action of pharmacologic vitreolysis
- Discuss the available data on the safety and efficacy of vitreolysis agents for PVD induction
- Understand the importance of patient selection for pharmacologic PVD
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Dulaney Foundation and Retina Today. The Dulaney Foundation is accredited by the ACCME to provide continuing edu- cation for physicians. The Dulaney Foundation designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participation Method
Participants should read the CME activity in its entirety. After reviewing the material, please complete the self-assessment test, which consists of a series of multiple-choice questions. To answer these questions online and receive real-time results, please visit http://www.dulaneyfoundation.org and click “Online Courses.” Upon completing the activity and achieving a passing score of over 70% on the self-assessment test, you may print out a CME credit letter awarding 1 AMA PRA Category 1 Credit.™ The estimated time to complete this activity is 1 hour. Faculty and Disclosures
DISCLOSURE POLICY
Carl D. Regillo, MD, is the Director of the Retina Service of Wills Eye Institute and a Professor of Ophthalmology at Thomas Jefferson University in Philadelphia. He is a member of the Retina Today Editorial Board. He may be reached at cregillo@aol.com. Peter K. Kaiser, MD, is a Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine and a staff surgeon in the Vitreoretinal Department at the Cole Eye Institute, Cleveland Clinic. He is a Retina Today Editorial Board member. Dr. Kaiser may be reached at pkkaiser@aol.com. Faculty/Staff Disclosure Declarations Dr. Regillo states that he receives grant research support from Alimera, Allergan, Genentech, Glaxo Smith Kline, Ophthotech, Regeneron, ThromboGenics, Advanced Cell Technology, Johnson and Johnson, QLT, and Alcon Laboratories, Inc. He is a consultant and speaker for Alimera, Alcon, Genentech, GlaxoSmithKline, and Regeneron. Dr. Kaiser states that he has received research funding from Acucela, Alimera, Allergan, National Institutes of Health, Novartis, LPath, Research to Prevent Blindness, National Eye Institute, Genentech, Pfizer, Potentia, and Regeneron. He is a consultant to Alcon, Alimera, Allegro Ophthalmics, Arctic Dx, Bausch + Lomb, Bayer, Carl Zeiss Meditec, Genentech, GlaxoSmithKline, InSitu Therapeutics, Kanghong Biotech, LPath, Novartis, Ophthotec, Oraya, and Regeneron. All of those involved in the planning, editing, and peer review of this educational activity report no financial relationships.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
In accordance with the disclosure policies of the Dulaney Foundation and to conform with ACCME and US Food and Drug Administration guidelines, anyone in a position to affect the content of a CME activity is required to disclose to the activity participants (1) the existence of any financial interest or other relationships with the manufacturers of any commercial products/ devices or providers of commercial services and (2) identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The Dulaney Foundation, Retina Today, or ThromboGenics. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal - CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 credit
Deepak Sambhara, MD
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
